allowed for the precise and potent release of cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and programmed cell death-ligand 1 (PD-L1), resulting in a significant increase in the therapeutic efficacy for tumor regression (Gurbatri et al., 2020). This evidence concerns the gene CTLA4 and neoplasm.